Final patient enrolled in Veyonda's LuPIN study

Latest News

Noxopharm (ASX:NOX) has announced that the last patient has been enrolled and safely dosed in the ongoing LuPIN Phase 1/2 clinical trial being conducted by St Vincent’s Hospital Sydney.

It said this completes patient recruitment for the study and brings the total number of participants to 56.

The LuPIN study is an investigator-initiated clinical trial evaluating Noxopharm's lead product candidate, Veyonda, in combination with radiopharmaceutical 177Lu-PSMA-617. The treatment is being trialled in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC) that have failed to respond to all standard therapies and have limited survival prospects.

According to Dr Gisela Mautner, Noxopharm chief medical officer, “We are extremely pleased that the last patient has been successfully dosed in the LuPIN trial. It is an important milestone that significantly de-risks the study. We sincerely thank the principal investigators at St Vincent’s Hospital Sydney, the participating patients and their families for being part of this study.

“The LuPIN study recently has shown a pronounced survival benefit in an interim analysis of 32 patients, with a median Overall Survival of 17.1 months, and continues to report an excellent safety profile for the combination treatment. This is a remarkable outcome for end-stage prostate cancer patients.”

Associate Professor Dr Louise Emmett of St Vincent’s Hospital Sydney and principal investigator of LuPIN, said, “It was a great pleasure to run the LuPIN trial and we were able to enrol patients into the study very quickly. Developing a new treatment option for late-stage prostate cancer patients is very important as their expected survival and quality of life can be very poor. I am glad we were able to help many men who had no further treatment options left.”

The company said further interim data from the Phase LuPIN study is expected later this year, with a final read-out anticipated in mid-2021.